Metoject Pen

Methotrexate, the active ingredient in Metoject Pen, is an antimetabolite (folate antagonist) presented as a pre‑filled pen injector for subcutaneous use. It is employed to treat rheumatoid arthritis, psoriasis, acute lymphoblastic leukaemia and other malignancies in adult and paediatric patients. GNH USA supplies Metoject Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts as a disease‑modifying agent across several immune‑mediated and oncologic conditions.

Rheumatoid arthritis: reduces joint inflammation and slows structural damage. Psoriasis: improves skin lesions and decreases plaque formation. Acute lymphoblastic leukaemia: interferes with malignant cell proliferation as part of chemotherapy protocols. Other malignancies: incorporated into combination regimens to inhibit tumour growth.

Methotrexate may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea or vomiting. - Fatigue and mild headache. - Oral ulceration or mucositis. - Transient elevation of liver enzymes. - Mild cytopenias (low white cells or platelets). - Skin rash or itching.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Profound bone‑marrow suppression leading to pancytopenia. - Acute renal failure. - Life‑threatening infections due to immunosuppression. - Anaphylactic or severe hypersensitivity reactions.

Before initiating therapy, clinicians should assess patient suitability and monitor key parameters.

Pregnancy: contraindicated (Category X) – avoid use in pregnant women. Renal function: evaluate baseline creatinine; adjust or avoid in significant impairment. Liver function: monitor transaminases regularly; avoid in severe hepatic disease. Infection risk: screen for latent infections and monitor for new infections during treatment. Drug monitoring: perform complete blood counts frequently to detect cytopenias early. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can increase toxicity or require dose adjustments.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (omeprazole, esomeprazole): may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Azathioprine: combined immunosuppression may require monitoring. - Penicillamine: may increase methotrexate toxicity. - High‑dose acetaminophen: potential additive liver injury.